A
Allogene Therapeutics, Inc. (ALLO)
NMS – Real Time Price. Currency in USD
2.30
+0.02 (0.88%)
At close: May 12, 2026, 4:00 PM EDT
2.31
+0.01 (0.62%)
After-hours: May 12, 2026, 7:58 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
2.30
+0.02 (0.88%)
At close: May 12, 2026, 4:00 PM EDT
2.31
+0.01 (0.62%)
After-hours: May 12, 2026, 7:58 PM EDT
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
| Name | Position |
|---|---|
| Dr. Arie S. Belldegrun F.A.C.S., M.D. | Co-Founder & Executive Chairman |
| Dr. David D. Chang M.D., Ph.D. | Co-Founder, President, CEO & Director |
| Dr. Zachary J. Roberts M.D., Ph.D. | Executive VP of Research & Development and Chief Medical Officer |
| Mr. Benjamin M. Beneski | Senior VP & Chief Technical Officer |
| Mr. Earl M. Douglas Esq. | Senior VP, General Counsel, Compliance Officer & Corporate Secretary |
| Mr. Geoffrey M. Parker | Executive VP & CFO |
| Mr. Joshua A. Kazam | Co-Founder & Director |
| Ms. Annie Yoshiyama | SVP & Corporate Controller |
| Ms. Christine Cassiano | Executive VP, Chief Corporate Affairs & Brand Strategy Officer |
| Ms. Susan R. Lundeen | Chief People Officer |
| Date | Type | Document |
|---|---|---|
| 2026-04-30 | DEF 14A | allo-20260430.htm |
| 2026-04-20 | PRE 14A | allo-20260420.htm |
| 2026-04-15 | 8-K | d283634d8k.htm |
| 2026-04-13 | 8-K | d249901d8k.htm |
| 2026-03-12 | 8-K | allo-20260312.htm |
| 2025-11-06 | 8-K | allo-20251106.htm |
| 2025-11-06 | 10-Q | allo-20250930.htm |
| 2025-10-14 | 8-K | allo-20250926.htm |
| 2025-08-13 | 8-K | allo-20250813.htm |
| 2025-08-01 | 8-K | d75167d8k.htm |